Prof John Dillon is Professor of Hepatology and Gastroenterology, in the School of Medicine, Ninewells Hospital, University of Dundee, as well as being an honorary consultant with NHS Tayside, leading a busy general hepatology service and a research group. He is also clinical lead for Blood Borne Viruses in Tayside. He was a NHS consultant Physician, Gastroenterologist and Hepatologist in Tayside for over 10 years, prior to his move to the University of Dundee. He chairs the Scottish HCV action plan clinical leads group and is a member of the ministerial advisory group for sexual health and blood borne viruses, as well as chairing the Scottish Liver Diagnostic Care Pathway Steering Group on behalf of Scottish Government. Previously he chaired the testing treatment and care working group of phase 1 of the Scottish Government HCV action Plan and the Hepatitis C SIGN guideline development group. He graduated in Medicine from St George’s Hospital Medical School, University of London, and subsequently gained his MD based on research performed in the University of Edinburgh while a lecturer in Gastroenterology and Hepatology.

Evidence of continued injecting drug use after attaining sustained treatment-induced clearance of the hepatitis C virus: Implications for reinfection. Heather Valerio, David J Goldberg, James Lewsey, Amanda Weir, Samuel Allen, Esther J Aspinall, Stephen T Barclay, Peter Bramley, John F Dillon, Ray Fox, Andrew Fraser, Peter C Hayes, Hamish Innes, Nicholas Kennedy, Peter R Mills, Adrian J Stanley, Sharon J Hutchinson. Drug and alcohol dependence, 2015;154:125-131. Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy: Scotland's experience. Sharon J. Hutchinson, John F. Dillon, Ray Fox, Scott A. McDonald, Hamish A. Innes, Amanda Weir, Allan McLeod, Esther J. Aspinall, Esther J. Aspinall, Norah E. Palmateer, Avril Taylor, Alison Munro, Heather Valerio, Heather Valerio, Gareth Brown, David J. Goldberg et al International Journal of Drug Policy 06/2015; 57. The effect of introducing point-of-care or dried blood spot analysis on the uptake of hepatitis C virus testing in high-risk populations. A systematic review of the literature. JT Coates, John F Dillon. International Journal of Drug Policy 2015; 06/2015; Towards a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hamish Innes, Scott A McDonald, John F Dillon, David Goldberg, Stephen T Barclay, Heather Valerio, Ray Fox, Diptendu Bhattacharyya, Andrew Fraser, Peter Bramley, Sharon J Hutchinson. Hepatology. 2015; 62: 355-364. Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease. Kayleigh L Wood, Michael H Miller and John F Dillon. BMJ Open Gastroenterology 2015 HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: Real world results and modelling of treatment impact. Natasha K. Martin, Graham R. Foster, J. Vilar, Stephen D. Ryder, Matthew E. Cramp, F. Gordon, John F. Dillon, Noel Craine, H. Busse, Amanda J. Clements, Sharon J. Hutchinson, Andrew P. Ustianowski, M. Ramsay, David J. Goldberg, William L. Irving, Vivian D. Hope, Daniela Souza Araújo De Angelis, Marion K. Lyons, Peter T. Vickerman, Matthew Hickman. Journal of Viral Hepatitis 2015;22:399-408 Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public-health outcomes do we value. Hamish Innes, John F Dillon, David Goldberg, and Sharon J Hutchinson. Gut 2014 11/2014 Epidemiology and Population Health"A Systematic Review of the Prevalence of Mildly Abnormal Liver Function Tests and Associated Health Outcomes" Sven Radcke, Aja Louise Murray, John F. Dillon, European Journal of Gastroenterology and Hepatology 2015;27:1-7. What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C? McDonald, S. A., Innes, H. A., Hayes, P. C., Dillon, J. F., Mills, P. R., Goldberg, D. J., Barclay, S., Allen, S., Fox, R., Fraser, A., Kennedy, N., Bhattacharyya, D. & Hutchinson, S. J. Journal of Hepatology 2015; 62:262-268. Uptake of hepatitis C specialist services and treatment following diagnosis by dried blood spot in Scotland. McAllister, G., Innes, H., Mcleod, A., Dillon, J. F., Hayes, P. C., Fox, R., Barclay, S. T., Templeton, K., Aitken, C., Gunson, R., Goldberg, D. & Hutchinson, S. J. Journal of Clinical Virology 2014;61:359-364. Health State Utilities Associated with Attributes of Treatments for Hepatitis C. Matza LS, Sapra S, Kalsekar A, Dillon JF, Davies E, Devine MK, Jordan J, Landrian A, Feeny DH. European Journal of Health Economics 2014;10. M Anwar, MH Miller, JF Dillon. Systematic review of association of serum bilirubin levels and non-alcoholic fatty liver disease: a feasible therapeutic avenue? World Journal of Pharmacology 2014;3: 209-216. Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes, but not with insulin resistance. Paul J. Meakin, Sudhir Chowdhry, Ritu S. Sharma, Fiona B. Ashford, Shaun V. Walsh, Rory J. McCrimmon, Albena T. Dinkova-Kostova, John F. Dillon, John D. Hayes, Michael L.J. Ashford. Molecular and Cell Biology 2014 Prediction of liver disease in patients whose liver function tests have been checked in primary care: model development and validation using population-based observational cohorts. David J McLernon, Peter T Donnan, Frank M Sullivan, Paul Roderick, William M Rosenberg, Steve D Ryder, John F Dillon. BMJ open 2014 The Serum Proteome of Non-Alcoholic Fatty Liver Disease - A multimodal approach to discovery of biomarkers of Non-Alcoholic Steatohepatitis. MH Miller, SV Walsh, A Atirh, JTJ Huang, MAJ Ferguson, JF Dillon. Journal of Gastroenterology and Hepatology. 2014 Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model. Hamish Innes, David Goldberg, Geoffrey Dusheiko, Peter Hayes, Peter R. Mills, John F. Dillon, Esther Aspinall, Stephen T. Barclay, Sharon J. Hutchinson Journal of Hepatology. 2014; Lifestyle interventions for the treatment of non-alcoholic fatty liver disease V Bradford, JF Dillon, MH Miller. Hepatic Medicine: Evidence and Research 2014;6:1–10. McDonald SA, Hutchinson SJ, Innes HA, Allen S, Bramley P, Bhattacharyya D, Carman W, Dillon JF, Fox R, Fraser A, Goldberg DJ, Kennedy N, Mills PR, Morris J, Stanley AJ, Wilks D, Hayes PC. Attendance at specialist hepatitis clinics and initiation of antiviral treatment among persons chronically infected with hepatitis C: examining the early impact of Scotland’s Hepatitis C Action Plan. Journal of Viral Hepatitis. 2014;21:. Innes HA, Hutchinson SJ, Barclay S, Cadzow E, Dillon JF, Fraser A, Goldberg DJ, Mills PR, McDonald SA, Morris J, Stanley A, Hayes P. Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness. Hepatology 2013 Feb; 57 (2): 451-60. Dry blood spot testing for hepatitis C in people who injected drugs: reaching the populations other tests cannot reach. J M Tait, Brian P Stephens, Paul G McIntyre, Morgan Evans, John F Dillon. Oesophageal bacterial biofilm changes in gastro-oesophageal reflux disease, Barrett's and oesophageal carcinoma: association or causality? Blackett, K. L., Siddhi, S. S., Cleary, S., Steed, H., Miller, M. H., Macfarlane, S., Macfarlane, G. T. & Dillon, J. F. Alimentary Pharmacology & Therapeutics. 2013; 37: 1084-1092. HCV treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Natasha K Martin, Peter Vickerman, Jason Grebely, Margaret Hellard, Sharon J Hutchinson, Viviane D Lima, Graham R Foster, John F Dillon, David J Goldberg, Gregory J Dore, Matthew Hickman. Hepatology 2013; 58: 1598-609. Richard S Tedder and Alison J Rodger, Lori Fries, Samreen Ijaz, Mark Thursz , William Rosenberg, Nikolai Naoumov, Jangu Banatvala, Roger Williams, Geoffrey Dusheiko, Shilpa Chokshi, Terry Wong, Gillian Rosenberg, Sulleman Moreea, Margaret Bassendine, Michael Jacobs, Peter Mills, David Mutimer, Stephen Ryder, Andrew Bathgate, Hyder Hussaini, John Dillon, Mark Wright, George Bird, Jane Collier, Michael Anderson, Anne Johnson for the CUSHI B Study Group. "The Diversity and Management of Chronic Hepatitis B Virus Infections in the UK - A Wake up Call," Clinical Infectious Diseases 2013 56: 951-60. DJ McLeron, PT Donnan, JF Dillon "Prevalence estimates of diagnosed viral hepatitis B, liver condition outcomes and hospitalisation costs: A population record-linkage study in Tayside, Scotland" Epidemiology and Infection 2013;141: 2122-2130. David J McLernon, John F Dillon, Frank M Sullivan, Paul Roderick, William M Rosenberg, Stephen D Ryder, PT Donnan. The utility of liver function tests for mortality prediction within one year in primary care using the Algorithm for Liver Function Investigations (ALFI). PLOS ONE 2012 7(12):